journal
https://read.qxmd.com/read/37852214/involvement-of-plasma-melatonin-in-medication-overuse-headache-a-cross-sectional-study
#21
JOURNAL ARTICLE
Huimin Tao, Qi Wan, Mei Sun, Kefu Cai, Yan Song, Mingqing He, Jiabing Shen
OBJECTIVES: Patients with medication-overuse headache (MOH) are often complicated with anxiety, depression, and sleep disorders and are associated with dependence behavior and substance abuse. Melatonin has physiological properties including analgesia, regulation of circadian rhythms, soporific, and antidepressant and affects drug preference and addiction. This study aimed to investigate the role of melatonin in MOH compared with episodic migraine (EM) and healthy controls and to verify the relationship between plasma melatonin levels and psychiatric symptoms...
October 19, 2023: Clinical Neuropharmacology
https://read.qxmd.com/read/37852213/consciousness-recovery-in-traumatic-brain-injury-a-systematic-review-comparing-modafinil-and-amantadine
#22
JOURNAL ARTICLE
Ali Seifi, Sina Hassannezhad, Reza Mosaddeghi-Heris, Arash Haji Kamanaj Olia, Ali Adib, Shaheryar Hafeez, Colleen Barthol
OBJECTIVES: Acute traumatic brain injury is one of the most common causes of death and disability. Reduction in the level of consciousness is a significant complication that can impact morbidity. Glasgow Coma Scale (GCS) is the most widely used method of assessing the level of consciousness. Neurostimulants such as amantadine and modafinil are common pharmacologic agents that increase GCS in patients with brain trauma. This study aimed to compare the effectiveness of these 2 drugs. METHODS: This systematic review obtained articles from Google Scholar, PubMed, Scopus, Embase, and MEDLINE databases...
October 19, 2023: Clinical Neuropharmacology
https://read.qxmd.com/read/37747824/neuroleptic-malignant-syndrome-in-patients-with-dementia-experiences-of-a-single-memory-clinic
#23
JOURNAL ARTICLE
Ahmet Turan Isik, Derya Kaya, Mehmet Selman Ontan, Feyza Mutlay, Esra Ates Bulut, Fatma Sena Dost, Neziha Erken, Ali Ekrem Aydin
OBJECTIVES: Neuroleptic malignant syndrome (NMS) is a life-threatening condition that occurs as an adverse reaction to antipsychotic and antiemetic agents or sudden withdrawal of dopaminergic medications. Given the metabolic and functional reserves and the comorbidities in older adults, NMS may show an atypical course. METHODS: The medical records of patients with neurodegenerative diseases leading to dementia between 2013 and 2020 were reviewed for the diagnosis of NMS...
September 19, 2023: Clinical Neuropharmacology
https://read.qxmd.com/read/37695864/undiagnosed-lambert-eaton-myasthenic-syndrome-in-the-era-of-sugammadex-a-case-report
#24
JOURNAL ARTICLE
Jenny J Yoon, Alexandra L Anderson, Adam D Niesen
OBJECTIVE: In this case report, we discuss the rare manifestation of prolonged neuromuscular blockade in a patient with history of small cell lung cancer and undiagnosed Lambert-Eaton myasthenic syndrome (LEMS) who had previously received succinylcholine for general anesthesia without incident but subsequently exhibited prolonged neuromuscular blockade during a laparoscopic procedure. We aimed to emphasize the importance of reversal agent safety and precision as well as vigilant perioperative and postoperative care...
September 12, 2023: Clinical Neuropharmacology
https://read.qxmd.com/read/37695861/changes-of-serum-c-reactive-protein-level-in-patients-with-depressive-disorders-after-treatment-with-agomelatine-combined-with-aerobic-exercise-and-its-significance
#25
JOURNAL ARTICLE
Zhuping Sun, Silu Chen, Hui Zhang, Xiaoqing Gu, Haiyan Ge, Jinglei Chen
OBJECTIVE: Depressive disorders constitute a series of debilitating diseases. This study investigated the therapeutic effect of agomelatine (AG) combined with aerobic exercise (AE) on patients with moderate-severe depression (MSD) and the changes of the serum C-reactive protein (CRP) level in patients after treatment as well as its significance. METHODS: A total of 178 MSD patients were randomly assigned to the AG group (N = 90) and AG + AE group (N = 88). The severity of depressive disorders and anhedonia was assessed using the Hamilton Rating Scale for Depression (HAM-D), Beck Depression Inventory, and Snaith-Hamilton Pleasure Scale scores...
September 12, 2023: Clinical Neuropharmacology
https://read.qxmd.com/read/37748004/three-cases-of-myoclonus-secondary-to-ciprofloxacin-ciproclonus
#26
JOURNAL ARTICLE
Hamna Javed, Hossam Tharwat Ali, Ziad Ashraf Soliman, Ana Leticia Fornari Caprara, Jamir Pitton Rissardo
OBJECTIVES: Ciprofloxacin is a fluoroquinolone that is used for bacterial infections involving different systems. In some cases, ciprofloxacin was reported to induce myoclonus. METHODS: We performed a chart review of 3 patients with myoclonus secondary to ciprofloxacin and reviewed the literature for similar cases. Written consent for publication was obtained from each patient, and their identities were concealed for ethical reasons. RESULTS: We describe 3 cases of myoclonus secondary to ciprofloxacin, 2 males and a female aged 61, 26, and 48 years, respectively...
September 2023: Clinical Neuropharmacology
https://read.qxmd.com/read/37748003/status-cataplecticus-induced-by-an-abrupt-duloxetine-withdrawal-a-case-report
#27
JOURNAL ARTICLE
Marek Cierny, John Feemster, Mohsin Hamid, Humberto A Battistini
In persons with narcolepsy type 1, sudden withdrawal of antidepressants can cause status cataplecticus. We describe a 77-year-old female patient with long-standing history of narcolepsy type 1 complaining of recurrent short sudden episodes of whole-body paralysis, with preserved consciousness and memory. Episodes started an hour after her family invited her to celebrate Mother's Day. One week prior, patient had abruptly discontinued duloxetine. Cataplectic episodes resolved within 24 hours after resumption of duloxetine and treatment of hypokalemia...
September 2023: Clinical Neuropharmacology
https://read.qxmd.com/read/37748002/changes-of-serum-c-reactive-protein-level-in-patients-with-depressive-disorders-after-treatment-with-agomelatine-combined-with-aerobic-exercise-and-its-significance
#28
JOURNAL ARTICLE
Zhuping Sun, Silu Chen, Hui Zhang, Xiaoqing Gu, Haiyan Ge, Jinglei Chen
OBJECTIVE: Depressive disorders constitute a series of debilitating diseases. This study investigated the therapeutic effect of agomelatine (AG) combined with aerobic exercise (AE) on patients with moderate-severe depression (MSD) and the changes of the serum C-reactive protein (CRP) level in patients after treatment as well as its significance. METHODS: A total of 178 MSD patients were randomly assigned to the AG group (N = 90) and AG + AE group (N = 88). The severity of depressive disorders and anhedonia was assessed using the Hamilton Rating Scale for Depression (HAM-D), Beck Depression Inventory, and Snaith-Hamilton Pleasure Scale scores...
September 2023: Clinical Neuropharmacology
https://read.qxmd.com/read/37748001/correlation-of-obesity-and-clinical-characteristics-in-drug-naive-first-episode-patients-with-schizophrenia
#29
JOURNAL ARTICLE
Na Li, Hua Xue, Yong Li, Minglong Gao, Ming Yu, Cuixia An, Chaomin Wang
OBJECTIVES: This study was aimed at investigating the prevalence of obesity in drug-naive first-episode (DNFE) patients with schizophrenia and its association with metabolic parameters, psychopathological symptoms, and cognitive function. METHODS: We collected general information on 411 DNFE schizophrenia patients and divided them into obese and nonobese groups according to body mass index (BMI). Glucolipid metabolic parameters of patients were collected. Positive and Negative Syndrome Scale was performed for assessing patients' psychopathological symptoms...
September 2023: Clinical Neuropharmacology
https://read.qxmd.com/read/37748000/medication-overuse-headache-chronic-migraine-and-monoclonal-antibodies-anti-cgrp-a-real-world-study
#30
JOURNAL ARTICLE
Abouch Krymchantowski, Carla Jevoux, Ana Gabriela Krymchantowski, Raimundo Pereira Silva-Néto
OBJECTIVE: Medication overuse headache (MOH) in chronic migraineurs may be a cause or consequence of the overuse of symptomatic medications for headache attacks. It is highly prevalent in tertiary centers. We compared the efficacy of 3 anti-CGRP monoclonal antibodies with traditional pharmacological agents in patients with chronic migraine (CM) and MOH. METHODS: A randomized, cross-sectional, prospective, and open trial with real-world comparison groups was carried out...
September 2023: Clinical Neuropharmacology
https://read.qxmd.com/read/37747999/reboxetine-combination-therapy-with-fluoxetine-in-moderate-to-severe-obsessive-compulsive-disorder-a-placebo-controlled-double-blind-randomized-trial
#31
JOURNAL ARTICLE
Erfaneh Hajian Tilaki, Alireza Hasanzadeh, Mohammadreza Shalbafan, Hossein Sanjari Moghaddam, Ahmad Shamabadi, Mahsa Boroon, Shahin Akhondzadeh
OBJECTIVES: Reboxetine is a potent and selective norepinephrine reuptake inhibitor that was effective in combination with citalopram for resistant obsessive-compulsive disorder (OCD). This study aims to assess its effectiveness and tolerability in combination with fluoxetine in treating OCD. METHODS: In this 2-center, placebo-controlled, and double-blind, randomized clinical trial, 76 patients with OCD were assigned into 2 parallel groups to receive fluoxetine (up to 80 mg/d) plus placebo (F + P) or fluoxetine (up to 80 mg/d) plus reboxetine (F + R) (10 mg twice daily) for 10 weeks...
September 2023: Clinical Neuropharmacology
https://read.qxmd.com/read/37747998/effects-of-amantadine-sulfate-on-motor-impairment-and-execution-of-motor-sequences-in-patients-with-parkinson-disease
#32
JOURNAL ARTICLE
Thomas Müller, Wilfried Kuhn
BACKGROUND: Intravenous application of amantadine sulfate induces a rapid improvement of motor behavior in patients with Parkinson disease. OBJECTIVES: To determine efficacy of daily infusion of 200 mg amantadine sulfate on scored motor symptoms and performance of standardized movement sequences with components of low and high cognitive efforts. METHODS: Thirty-one participants received infusions of amantadine sulfate in addition to their previous stable drug regimens on 3 consecutive days...
September 2023: Clinical Neuropharmacology
https://read.qxmd.com/read/37747997/amantadine-for-refractory-tremor-in-parkinson-disease-and-other-indications-a-chart-review-with-long-term-follow-up
#33
JOURNAL ARTICLE
Joseph H Friedman
OBJECTIVES: The aim of this study was to determine how amantadine was used in a movement disorders clinic and how effective it was. METHODS: A chart review over a 2-month period in 2022 of all patients in a movement disorders clinic who had ever taken amantadine was undertaken. RESULTS: One hundred six charts were included. Amantadine was initiated primarily for tremor and secondly for l -dopa-induced dyskinesias (LIDs). Sixty-two percent of tremor patients improved and tolerated amantadine; 74% of those with LID improved and tolerated the drug...
September 2023: Clinical Neuropharmacology
https://read.qxmd.com/read/37526628/effects-of-amantadine-sulfate-on-motor-impairment-and-execution-of-motor-sequences-in-patients-with-parkinson-disease
#34
JOURNAL ARTICLE
Thomas Müller, Wilfried Kuhn
BACKGROUND: Intravenous application of amantadine sulfate induces a rapid improvement of motor behavior in patients with Parkinson disease. OBJECTIVES: To determine efficacy of daily infusion of 200 mg amantadine sulfate on scored motor symptoms and performance of standardized movement sequences with components of low and high cognitive efforts. METHODS: Thirty-one participants received infusions of amantadine sulfate in addition to their previous stable drug regimens on 3 consecutive days...
July 31, 2023: Clinical Neuropharmacology
https://read.qxmd.com/read/37526626/three-cases-of-myoclonus-secondary-to-ciprofloxacin-ciproclonus
#35
JOURNAL ARTICLE
Hamna Javed, Hossam Tharwat Ali, Ziad Ashraf Soliman, Ana Leticia Fornari Caprara, Jamir Pitton Rissardo
OBJECTIVES: Ciprofloxacin is a fluoroquinolone that is used for bacterial infections involving different systems. In some cases, ciprofloxacin was reported to induce myoclonus. METHODS: We performed a chart review of 3 patients with myoclonus secondary to ciprofloxacin and reviewed the literature for similar cases. Written consent for publication was obtained from each patient, and their identities were concealed for ethical reasons. RESULTS: We describe 3 cases of myoclonus secondary to ciprofloxacin, 2 males and a female aged 61, 26, and 48 years, respectively...
July 27, 2023: Clinical Neuropharmacology
https://read.qxmd.com/read/37459400/reboxetine-combination-therapy-with-fluoxetine-in-moderate-to-severe-obsessive-compulsive-disorder-a-placebo-controlled-double-blind-randomized-trial
#36
JOURNAL ARTICLE
Erfaneh Hajian Tilaki, Alireza Hasanzadeh, Mohammadreza Shalbafan, Hossein Sanjari Moghaddam, Ahmad Shamabadi, Mahsa Boroon, Shahin Akhondzadeh
OBJECTIVES: Reboxetine is a potent and selective norepinephrine reuptake inhibitor that was effective in combination with citalopram for resistant obsessive-compulsive disorder (OCD). This study aims to assess its effectiveness and tolerability in combination with fluoxetine in treating OCD. METHODS: In this 2-center, placebo-controlled, and double-blind, randomized clinical trial, 76 patients with OCD were assigned into 2 parallel groups to receive fluoxetine (up to 80 mg/d) plus placebo (F + P) or fluoxetine (up to 80 mg/d) plus reboxetine (F + R) (10 mg twice daily) for 10 weeks...
July 18, 2023: Clinical Neuropharmacology
https://read.qxmd.com/read/37459397/status-cataplecticus-induced-by-an-abrupt-duloxetine-withdrawal-a-case-report
#37
JOURNAL ARTICLE
Marek Cierny, John Feemster, Mohsin Hamid, Humberto A Battistini
In persons with narcolepsy type 1, sudden withdrawal of antidepressants can cause status cataplecticus. We describe a 77-year-old female patient with long-standing history of narcolepsy type 1 complaining of recurrent short sudden episodes of whole-body paralysis, with preserved consciousness and memory. Episodes started an hour after her family invited her to celebrate Mother's Day. One week prior, patient had abruptly discontinued duloxetine. Cataplectic episodes resolved within 24 hours after resumption of duloxetine and treatment of hypokalemia...
July 18, 2023: Clinical Neuropharmacology
https://read.qxmd.com/read/37399328/correlation-of-obesity-and-clinical-characteristics-in-drug-naive-first-episode-patients-with-schizophrenia
#38
JOURNAL ARTICLE
Na Li, Hua Xue, Yong Li, Minglong Gao, Ming Yu, Cuixia An, Chaomin Wang
OBJECTIVES: This study was aimed at investigating the prevalence of obesity in drug-naive first-episode (DNFE) patients with schizophrenia and its association with metabolic parameters, psychopathological symptoms, and cognitive function. METHODS: We collected general information on 411 DNFE schizophrenia patients and divided them into obese and nonobese groups according to body mass index (BMI). Glucolipid metabolic parameters of patients were collected. Positive and Negative Syndrome Scale was performed for assessing patients' psychopathological symptoms...
July 4, 2023: Clinical Neuropharmacology
https://read.qxmd.com/read/37399318/amantadine-for-refractory-tremor-in-parkinson-disease-and-other-indications-a-chart-review-with-long-term-follow-up
#39
JOURNAL ARTICLE
Joseph H Friedman
OBJECTIVES: The aim of this study was to determine how amantadine was used in a movement disorders clinic and how effective it was. METHODS: A chart review over a 2-month period in 2022 of all patients in a movement disorders clinic who had ever taken amantadine was undertaken. RESULTS: One hundred six charts were included. Amantadine was initiated primarily for tremor and secondly for l-dopa-induced dyskinesias (LIDs). Sixty-two percent of tremor patients improved and tolerated amantadine; 74% of those with LID improved and tolerated the drug...
July 4, 2023: Clinical Neuropharmacology
https://read.qxmd.com/read/37367203/obsessive-compulsive-psychotic-and-autism-dimensions-overlap-in-real-world-a-case-report
#40
JOURNAL ARTICLE
Mauro Scala, Laura Biondi, Alessandro Serretti, Chiara Fabbri
BACKGROUND: Obsessions, compulsions, and stereotypes are common psychopathological manifestations of obsessive-compulsive, psychotic, and autism spectrum disorders (ASDs). These nosological entities may be present in comorbidity, with relevant clinical difficulties in the differential diagnosis process. Moreover, ASDs are a complex group of disorders, with a childhood onset, which also persist into adulthood and present heterogeneous symptom patterns that could be confused with psychotic disorders...
June 21, 2023: Clinical Neuropharmacology
journal
journal
26752
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.